Please login to the form below

Not currently logged in

Mylan to develop Lantus, Humalog and NovoLog generics

Signs Indian biotech deal to compete with the big-selling insulin brands

Mylan has set its sights on bringing generic versions of three top-selling insulin brands to market.

The company has signed a collaboration deal with Biocon to develop and commercialise the Indian biotech firm's versions of Sanofi's Lantus, Lilly's Humalog and Novo Nordisk's NovoLog.

Together the three 'fast-acting' insulin brands are worth approximately $11.5bn and all three are expected to lose patent protection in the next couple of years.

Mylan hopes its deal with Biocon will allow it to be one of the first companies to launch generic versions of the insulins in developed pharma markets like the US.

Mylan's CEO Heather Bresch said: "This collaboration further expands and diversifies our pipeline of complex, difficult-to-manufacture products with strong future growth potential.

“Importantly, we believe we have the opportunity to be one of the first generic entrants in developed markets into the rapidly growing diabetes area, helping to address unmet needs and reduce the economic burden to those battling the disease and to the global healthcare system."

The collaboration, which adds to the US generics company's existing generic biologics partnership with Biocon, will see the firms share development, capital and certain other costs in order to bring the products to market.

Mylan will then have exclusive commercialisation rights in the US, Canada, Australia, New Zealand, the EU and European Free Trade Association countries through a profit-share arrangement with Biocon.

Mylan will also have co-exclusive commercialisation rights with Biocon in certain other markets around the world.

Biocon's chairman and managing director Kiran Mazumdar-Shaw said: "We are confident that together we can build a strong global presence in generic insulin analogs and provide access to affordable therapy options to physicians, healthcare providers and diabetes patients worldwide."

Established in 1978, Biocon is India's largest biotechnology company by revenue and its product portfolio includes the world's first Pichia-based recombinant human insulin, Insugen.

14th February 2013

From: Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...